Bavarian Nordic hunting for RSV partners: "If the firm is too small, we might as well consider launching ourselves"

Bavarian Nordic’s recent deal in China has some pundits guessing that more partnerships are on the way. Even so, the company’s CFO Henrik Juuel says if the bidders aren’t the right size, it might be in Bavarian’s best interest to commercialize its RSV vaccine itself.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

As the ink dries on the deal Bavarian Nordic just signed with a Shanghai-based partner, a question emerges: Having found a partner in China, what will the Danish pharmaceutical firm do with its RSV vaccine candidate in the US and Europe?

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading